Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Tumor infiltrating B-cells are increased in prostate cancer tissue

Authors: Jason R Woo, Michael A Liss, Michelle T Muldong, Kerrin Palazzi, Amy Strasner, Massimo Ammirante, Nissi Varki, Ahmed Shabaik, Stephen Howell, Christopher J Kane, Michael Karin, Christina AM Jamieson

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The presence of increased B-cell tumor infiltrating lymphocytes (TILs) was seen in mouse prostate cancer (PCa) but has not been fully documented in human PCa. We, therefore, investigated the density of infiltrating B cells within human PCa utilizing a quantitative computational method.

Methods

Archived radical prostatectomy specimens from 53 patients with known clinical outcome and D’Amico risk category were obtained and immunohistochemically (IHC) stained for the B cell marker, CD20. Slides were reviewed by a genitourinary pathologist who manually delineated the tumoral regions of PCa. Slides were digitally scanned and a computer algorithm quantified the area of CD20 stained B-cells as a measure of B cell density within the outlined regions of prostate cancer (intra-tumoral region), versus extra-tumoral prostate tissue. Correlations were analyzed between B-cell density and demographic and clinical variables, including D’Amico risk groups and disease recurrence.

Results

For the entire cohort, the mean intra-tumoral B cell density was higher (3.22 SE = 0.29) than in the extra-tumoral region of each prostatectomy section (2.24, SE = 0.19) (paired t test; P < 0.001). When analyzed according to D’Amico risk group, the intra-tumoral B cell infiltration in low risk (0.0377 vs. 0.0246; p = 0.151) and intermediate risk (0.0260 vs. 0.0214; p = 0.579) patient prostatectomy specimens did not show significantly more B-cells within the PCa tumor. However, patient specimens from the high-risk group (0.0301 vs. 0.0197; p < 0.001) and from those who eventually had PCa recurrence or progression (0.0343 vs. 0.0246; p = 0.019) did show significantly more intra-tumoral CD20+ B-cell staining. Extent of B-cell infiltration in the prostatectomy specimens did not correlate with any other clinical parameters.

Conclusions

Our study shows that higher B-cell infiltration was present within the intra-tumoral PCa regions compared to the extra-tumoral benign prostate tissue regions in prostatectomy sections. For this study we developed a new method to measure B-cells using computer-assisted digitized image analysis. Accurate, consistent quantitation of B-cells in prostatectomy specimens is essential for future clinical trials evaluating the effect of B cell ablating antibodies. The interaction of B-cells and PCa may serve as the basis for new therapeutic targets.
Appendix
Available only for authorised users
Literature
1.
go back to reference May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW: Prostate cancer immunotherapy. Clin Cancer Res. 2011, 17: 5233-5238. 10.1158/1078-0432.CCR-10-3402.PubMedCentralCrossRefPubMed May KF, Gulley JL, Drake CG, Dranoff G, Kantoff PW: Prostate cancer immunotherapy. Clin Cancer Res. 2011, 17: 5233-5238. 10.1158/1078-0432.CCR-10-3402.PubMedCentralCrossRefPubMed
2.
go back to reference Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD: Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab Invest. 2009, 89: 142-151. 10.1038/labinvest.2008.123.CrossRefPubMed Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD: Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab Invest. 2009, 89: 142-151. 10.1038/labinvest.2008.123.CrossRefPubMed
3.
go back to reference Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD: Immune modulation in cancer with antibodies. Annu Rev Med. 2013, Epub ahead of print] Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD: Immune modulation in cancer with antibodies. Annu Rev Med. 2013, Epub ahead of print]
4.
go back to reference Schmidt M, Bohm D, von Torne C: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68: 5405-5413. 10.1158/0008-5472.CAN-07-5206.CrossRefPubMed Schmidt M, Bohm D, von Torne C: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68: 5405-5413. 10.1158/0008-5472.CAN-07-5206.CrossRefPubMed
5.
go back to reference Erdag G, Schaefer JT, Smolkin ME: Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012, 72: 1070-1080. 10.1158/0008-5472.CAN-11-3218.PubMedCentralCrossRefPubMed Erdag G, Schaefer JT, Smolkin ME: Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012, 72: 1070-1080. 10.1158/0008-5472.CAN-11-3218.PubMedCentralCrossRefPubMed
6.
go back to reference Nielsen JS, Sahota RA, Milne K: CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012, 18: 3281-3292. 10.1158/1078-0432.CCR-12-0234.CrossRefPubMed Nielsen JS, Sahota RA, Milne K: CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012, 18: 3281-3292. 10.1158/1078-0432.CCR-12-0234.CrossRefPubMed
7.
go back to reference Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008, 14: 5220-5227. 10.1158/1078-0432.CCR-08-0133.CrossRefPubMed Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008, 14: 5220-5227. 10.1158/1078-0432.CCR-08-0133.CrossRefPubMed
8.
go back to reference Fujii T, Shimada K, Asai O: Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology. 2013, 80: 119-126. 10.1159/000342396.CrossRefPubMed Fujii T, Shimada K, Asai O: Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology. 2013, 80: 119-126. 10.1159/000342396.CrossRefPubMed
9.
go back to reference Gannot G, Richardson AM, Rodriguez-Canales J: Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer. Am J Cancer Res. 2011, 1: 120-127.PubMedCentralPubMed Gannot G, Richardson AM, Rodriguez-Canales J: Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer. Am J Cancer Res. 2011, 1: 120-127.PubMedCentralPubMed
10.
go back to reference Luo JL, Tan W, Ricono JM: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007, 446: 690-694. 10.1038/nature05656.CrossRefPubMed Luo JL, Tan W, Ricono JM: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007, 446: 690-694. 10.1038/nature05656.CrossRefPubMed
11.
go back to reference Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M: B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010, 464: 302-305. 10.1038/nature08782.PubMedCentralCrossRefPubMed Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M: B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010, 464: 302-305. 10.1038/nature08782.PubMedCentralCrossRefPubMed
12.
go back to reference Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M: An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev. 2013, 27: 1435-1440. 10.1101/gad.220202.113.PubMedCentralCrossRefPubMed Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M: An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev. 2013, 27: 1435-1440. 10.1101/gad.220202.113.PubMedCentralCrossRefPubMed
13.
go back to reference D'Amico AV, Whittington R, Malkowicz SB: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-974. 10.1001/jama.280.11.969.CrossRefPubMed D'Amico AV, Whittington R, Malkowicz SB: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-974. 10.1001/jama.280.11.969.CrossRefPubMed
14.
go back to reference Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, Leach RJ, Angata T, Varki N, Varki A: SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem. 2011, 286 (26): 23003-23011. 10.1074/jbc.M111.244152.PubMedCentralCrossRefPubMed Mitra N, Banda K, Altheide TK, Schaffer L, Johnson-Pais TL, Beuten J, Leach RJ, Angata T, Varki N, Varki A: SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J Biol Chem. 2011, 286 (26): 23003-23011. 10.1074/jbc.M111.244152.PubMedCentralCrossRefPubMed
16.
go back to reference Galon J, Costes A, Sanchez-Cabo F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed Galon J, Costes A, Sanchez-Cabo F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed
17.
go back to reference Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011, 105: 93-103. 10.1038/bjc.2011.189.PubMedCentralCrossRefPubMed Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011, 105: 93-103. 10.1038/bjc.2011.189.PubMedCentralCrossRefPubMed
18.
go back to reference Flammiger A, Bayer F, Cirugeda-Kuhnert A: Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012, 120: 901-908. 10.1111/j.1600-0463.2012.02924.x.CrossRefPubMed Flammiger A, Bayer F, Cirugeda-Kuhnert A: Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012, 120: 901-908. 10.1111/j.1600-0463.2012.02924.x.CrossRefPubMed
19.
go back to reference Hussein MR, Al-Assiri M, Musalam AO: Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009, 86 (2): 108-113. 10.1016/j.yexmp.2008.11.010.CrossRefPubMed Hussein MR, Al-Assiri M, Musalam AO: Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol. 2009, 86 (2): 108-113. 10.1016/j.yexmp.2008.11.010.CrossRefPubMed
20.
go back to reference Moser PL, Brunner A, Horninger W, Bartsch G, Mikuz G: Correlation between inflammatory cells in prostate biopsies and elevated PSA levels in a PSA screening population. Urology. 2002, 59: 68-72.CrossRefPubMed Moser PL, Brunner A, Horninger W, Bartsch G, Mikuz G: Correlation between inflammatory cells in prostate biopsies and elevated PSA levels in a PSA screening population. Urology. 2002, 59: 68-72.CrossRefPubMed
21.
go back to reference Kärjä V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R: Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 2005, 25: 4435-4438.PubMed Kärjä V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R: Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 2005, 25: 4435-4438.PubMed
22.
go back to reference Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis, Selective involvement with nonmalignant glands. Am J Surg Pathol. 1992, 16: 975-981. 10.1097/00000478-199210000-00008.CrossRefPubMed Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis, Selective involvement with nonmalignant glands. Am J Surg Pathol. 1992, 16: 975-981. 10.1097/00000478-199210000-00008.CrossRefPubMed
23.
go back to reference Ebelt K, Babaryka G, Figel AM: Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate. 2008, 68: 1-10. 10.1002/pros.20661.CrossRefPubMed Ebelt K, Babaryka G, Figel AM: Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate. 2008, 68: 1-10. 10.1002/pros.20661.CrossRefPubMed
24.
go back to reference Becker RL: Standardization and quality control of quantitative microscopy in pathology. J Cell Biochem Suppl. 1993, 17G: 199-204.CrossRefPubMed Becker RL: Standardization and quality control of quantitative microscopy in pathology. J Cell Biochem Suppl. 1993, 17G: 199-204.CrossRefPubMed
25.
go back to reference Franklin WA, Bibbo M, Doria MI: Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. Anal Quant Cytol Histol. 1987, 9: 279-286.PubMed Franklin WA, Bibbo M, Doria MI: Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. Anal Quant Cytol Histol. 1987, 9: 279-286.PubMed
26.
go back to reference Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM: Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997, 45 (11): 1559-1565. 10.1177/002215549704501112.CrossRefPubMed Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM: Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997, 45 (11): 1559-1565. 10.1177/002215549704501112.CrossRefPubMed
27.
go back to reference Braun M, Kirsten R, Rupp NJ: Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 2013, 28: 605-610.PubMed Braun M, Kirsten R, Rupp NJ: Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 2013, 28: 605-610.PubMed
28.
go back to reference McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA: The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004, 91: 541-543. 10.1038/sj.bjc.6601943.PubMedCentralCrossRefPubMed McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA: The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004, 91: 541-543. 10.1038/sj.bjc.6601943.PubMedCentralCrossRefPubMed
29.
go back to reference Irani JGJ, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N: High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology. 1999, 54: 467-472. 10.1016/S0090-4295(99)00152-1.CrossRefPubMed Irani JGJ, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N: High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology. 1999, 54: 467-472. 10.1016/S0090-4295(99)00152-1.CrossRefPubMed
30.
go back to reference Vesalainen S, Lipponen P, Talja M, Syrjanen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994, 30A: 1797-1803.CrossRefPubMed Vesalainen S, Lipponen P, Talja M, Syrjanen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994, 30A: 1797-1803.CrossRefPubMed
31.
go back to reference Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: IMPACT study investigators, sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363 (5): 411-422. 10.1056/NEJMoa1001294.CrossRefPubMed Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: IMPACT study investigators, sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363 (5): 411-422. 10.1056/NEJMoa1001294.CrossRefPubMed
32.
go back to reference Sharma P, Wagner K, Wolchok JD, Allison JP: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011, 11 (11): 805-812. 10.1038/nrc3153.PubMedCentralCrossRefPubMed Sharma P, Wagner K, Wolchok JD, Allison JP: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011, 11 (11): 805-812. 10.1038/nrc3153.PubMedCentralCrossRefPubMed
33.
go back to reference Slovin SF: Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. Immunotherapy. 2013, 5 (12): 1347-1355. 10.2217/imt.13.140.CrossRefPubMed Slovin SF: Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. Immunotherapy. 2013, 5 (12): 1347-1355. 10.2217/imt.13.140.CrossRefPubMed
Metadata
Title
Tumor infiltrating B-cells are increased in prostate cancer tissue
Authors
Jason R Woo
Michael A Liss
Michelle T Muldong
Kerrin Palazzi
Amy Strasner
Massimo Ammirante
Nissi Varki
Ahmed Shabaik
Stephen Howell
Christopher J Kane
Michael Karin
Christina AM Jamieson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-30

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.